Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132389 | 0.89 | CYP2C19 (0.43) | MGLLCASP6GFERMAPTKDM4E | |
| SCHEMBL16215112 | 0.88 | MGLL (0.40) | MGLLAKR1C3MAPTKDM4EEPHX2 | |
| SCHEMBL10131085 | 0.87 | MAPT (0.41) | MGLLPRKDCAKR1C3MAPTKDM4E | |
| SCHEMBL10131061 | 0.85 | MAPT (0.46) | MGLLAKR1C3MAPTKDM4ERAB9A | |
| SCHEMBL9951786 | 0.84 | GPR119 (0.49) | MGLLMAPTALDH1A1 | |
| SCHEMBL2713151 | 0.84 | GPR119 (0.49) | MGLLMAPTALDH1A1 | |
| SCHEMBL16215124 | 0.80 | DRD2 (0.43) | MAPTKDM4ERAB9AALDH1A1ALOX15 | |
| SCHEMBL10130983 | 0.80 | DRD2 (0.43) | MAPTKDM4ERAB9AALDH1A1ALOX15 | |
| SCHEMBL11617078 | 0.80 | MGLL (0.56) | MGLL | |
| SCHEMBL11612351 | 0.80 | MGLL (0.45) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| EP-2445887-B1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | MGLL 4807/4885PRKDC 2560/4885AKR1C3 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.